Ultimately, the insights provided in this work have distinct diagnostic implications and suggest the possibility that targeting MDM2 or ATRX by small molecule in a combination with CDK4 inhibitor might be promising for cancer therapy. This evidence concerns the gene CDK4 and cancer.